Pfizer 2010 Annual Report Download - page 38

Financial Review
Pfizer Inc. and Subsidiary Companies
•lower interest income of $344 million in 2010, primarily due to lower interest rates coupled with lower average investment balances; and
•the non-recurrence of a $482 million gain recorded in 2009 related to ViiV (see further discussion in the “Our Business Development
Initiatives” section of this Financial Review),
partially offset primarily by:
•higher royalty-related income of $336 million in 2010, primarily due to the addition of legacy Wyeth royalties.
2009 vs. 2008
Other deductions—net decreased by $1.7 billion in 2009, compared to 2008, which primarily reflects:
•the non-recurrence of charges recorded in 2008 of approximately $2.3 billion related to the resolution of certain investigations
concerning Bextra and various other products;
•the non-recurrence of litigation-related charges recorded in 2008 of approximately $900 million associated with the resolution of certain
litigation involving our non-steroidal anti-inflammatory (NSAID) pain medicines; and
•a $482 million gain recorded in 2009 related to ViiV (see further discussion in the “Our Business Development Initiatives” section of this
Financial Review),
partially offset by:
•higher interest expense of $717 million primarily associated with the $13.5 billion of senior unsecured notes that we issued in March
2009 and the approximately $10.5 billion of senior unsecured notes that we issued in June 2009, to partially finance the acquisition of
Wyeth, as well as the addition of legacy Wyeth debt;
•lower interest income of $542 million, primarily due to lower interest rates, partially offset by higher cash balances;
•asset impairment charges of $417 million, primarily associated with certain materials used in our research and development activities
that no longer were considered recoverable; and
•the non-recurrence of a one-time cash payment received in 2008 of $425 million, pre-tax, in exchange for the termination of a license
agreement, including the right to receive future royalties and a gain of $211 million related to the sale of a building in Korea.
For additional information about the asset impairment charges in each year, see the “Accounting Policies—Asset Impairment
Reviews—Long-Lived Assets” section of this Financial Review as well as Notes to Consolidated Financial Statements—Note 2.
Acquisition of Wyeth, Note 3B. Other Significant Transactions and Events: Asset Impairment Charges and Note 12B. Goodwill and
Other Intangible Assets: Other Intangible Assets.
Provision for Taxes on Income
During the fourth quarter of 2010, we reached a settlement with the U.S. Internal Revenue Service (IRS) related to issues we had
appealed with respect to the audits of the Pfizer Inc. tax returns for the years 2002 through 2005, as well as the Pharmacia audit for
the year 2003 through the date of merger with Pfizer (April 16, 2003). The IRS concluded its examination of the aforementioned tax
years and issued a final Revenue Agent’s Report (RAR). We have agreed with all of the adjustments and computations contained in
the RAR. As a result of settling these audit years, in the fourth quarter of 2010, we reduced our unrecognized tax benefits by
approximately $1.4 billion and reversed the related interest accruals by approximately $600 million, both of which had been
classified in Other taxes payable, and recorded a corresponding tax benefit in Provision for taxes on income (see Notes to
Consolidated Financial Statements––Note 7. Taxes on Income).
Our effective tax rate for continuing operations was 11.9% in 2010, 20.3% in 2009 and 17.0% in 2008. The lower tax rate in 2010
compared to 2009 is primarily the result of:
•the aforementioned $1.4 billion reduction in unrecognized tax benefits and $600 million in interest on these unrecognized tax benefits,
which were recorded as a result of the favorable tax audit settlement pertaining to prior years;
•a $320 million reduction in unrecognized tax benefits and $140 million in interest on these unrecognized tax benefits resulting from the
resolution of certain tax positions pertaining to prior years with various foreign tax authorities as well as from the expiration of the statute
of limitations; and
•the tax impact of the charge incurred for asbestos litigation,
partially offset by:
•higher expenses, incurred as a result of our acquisition of Wyeth, and the mix of jurisdictions in which those expenses were incurred;
•the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug
coverage, resulting from changes in the U.S. Healthcare Legislation concerning the tax treatment of that subsidy effective for tax years
beginning after December 31, 2012; and
36 2010 Financial Report